Kyorin Pharmaceutical has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its marketing application for the Eklira Genuair aclidinium bromide DPI for the treatment of COPD in 30 and 60 inhalation versions. Kyorin licensed Eklira Genuair from Almirall in February 2011.
The company also markets SkyePharma’s Flutiform fluticasone/formoterol MDI in Japan and launched a 120 inhalation version of that inhaler in December 2014.
Read the Kyorin Pharmaceutical press release.
